CN101073332A - Lipid-lowering biscuit - Google Patents
Lipid-lowering biscuit Download PDFInfo
- Publication number
- CN101073332A CN101073332A CNA2007100244237A CN200710024423A CN101073332A CN 101073332 A CN101073332 A CN 101073332A CN A2007100244237 A CNA2007100244237 A CN A2007100244237A CN 200710024423 A CN200710024423 A CN 200710024423A CN 101073332 A CN101073332 A CN 101073332A
- Authority
- CN
- China
- Prior art keywords
- ginseng
- pseudo
- effect
- blood
- syrup
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015895 biscuits Nutrition 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 244000131316 Panax pseudoginseng Species 0.000 claims description 25
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 25
- 240000007164 Salvia officinalis Species 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 23
- 235000005412 red sage Nutrition 0.000 claims description 23
- 241000112528 Ligusticum striatum Species 0.000 claims description 19
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 18
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 16
- 239000006188 syrup Substances 0.000 claims description 13
- 235000020357 syrup Nutrition 0.000 claims description 13
- 244000234609 Portulaca oleracea Species 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 235000001855 Portulaca oleracea Nutrition 0.000 claims description 9
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 8
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 8
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 8
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 8
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 8
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 8
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 8
- 240000000171 Crataegus monogyna Species 0.000 claims description 8
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 8
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 8
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 8
- 244000241872 Lycium chinense Species 0.000 claims description 8
- 235000015468 Lycium chinense Nutrition 0.000 claims description 8
- 244000292697 Polygonum aviculare Species 0.000 claims description 8
- 235000006386 Polygonum aviculare Nutrition 0.000 claims description 8
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 7
- 239000008157 edible vegetable oil Substances 0.000 claims description 7
- 235000013601 eggs Nutrition 0.000 claims description 7
- 235000013312 flour Nutrition 0.000 claims description 7
- 235000021552 granulated sugar Nutrition 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 6
- 210000002969 egg yolk Anatomy 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 102000002322 Egg Proteins Human genes 0.000 claims description 3
- 108010000912 Egg Proteins Proteins 0.000 claims description 3
- 235000008504 concentrate Nutrition 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 235000013345 egg yolk Nutrition 0.000 claims description 3
- 238000000465 moulding Methods 0.000 claims description 3
- 238000009955 starching Methods 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- 230000001737 promoting effect Effects 0.000 abstract description 14
- 235000013305 food Nutrition 0.000 abstract description 8
- 208000004880 Polyuria Diseases 0.000 abstract description 6
- 230000035619 diuresis Effects 0.000 abstract description 6
- 230000029087 digestion Effects 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 34
- 235000019197 fats Nutrition 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 12
- 208000008589 Obesity Diseases 0.000 description 10
- 235000020824 obesity Nutrition 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 2
- 235000019737 Animal fat Nutrition 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000723353 Chrysanthemum Species 0.000 description 2
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- MYBAONSAUGZRAX-UBQYYSLZSA-N Notoginsenoside Fe Chemical class C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O MYBAONSAUGZRAX-UBQYYSLZSA-N 0.000 description 2
- 201000002451 Overnutrition Diseases 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 2
- 239000009759 San-Chi Substances 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- UMFJAHHVKNCGLG-UHFFFAOYSA-N n-Nitrosodimethylamine Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 description 2
- 235000020823 overnutrition Nutrition 0.000 description 2
- -1 oxygen radical Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 2
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000131317 Capitulum Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010056328 Hepatic ischaemia Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000001716 anti-fugal effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 230000036279 refractory period Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 239000008946 yang xin Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a food composition for promoting digestion, removing food retention, promoting diuresis, excreting dampness, reducing blood fat and losing weight and a preparation method thereof. In addition, the invention can be used as common health care leisure food, has low price, no side effect, convenient eating and better economic and social benefits.
Description
Technical field
The present invention relates to the biscuit of a kind of food combination for the treatment of fat all cards and preparation method, especially promoting digestion and removing indigestion, clearing damp and promoting diuresis, lowering blood-fat and reducing weight.
Background technology
Obesity is meant that fat generation is too much in the human body, is divided into two classes usually, and a class is a Secondary Obesity, and it is accompanied by some disease and takes place, as the pancreas islet obesity, (this class obesity are extremely rare) such as the low property of thyroid function obesities.Second class is a simple obesity, it follows the variation of systems such as endocrine, mainly be because carbohydrate and animal fat intake have surpassed the consumption of human body, human body is converted into fat stores to unnecessary material at each tissue and subcutaneous and take place, the general fat deposition of the male sex is at belly, and the women is deposited on breast, buttocks, thigh top more.Usually it is many-sided causing fat reason, mainly contains the reason of aspects such as heredity, diet, motion, disease:
1, the gene of family's obesity.Scientists found at least at present 3 kinds with fat relevant genes, these genes can produce the protein that rolls up appetite, make absorption of human body in a large number above the heat of needs and cause fat.Confirm that according to the study have the overweight people more than 60%～80% that family history is arranged approximately, the someone adds up the children of 556 routine parents' obesities, obesity rates reaches 63%～87%.And normal parents' children, obesity rates only has 10%～36%, visible fat with hereditary closely related property.
2, overnutrition and hypomotility.Overnutrition or unbalance, gluttonous animal protein and fat, tobacco and wine are immoderate, do not add restraining, and it is irregular to live, lazy drowsiness.Hypomotility, be sitting in office, computer or television machine all day before, seldom participate in manual labor and take exercise; Bad adaptability is held pressure that can't stand modern allegro work and living environment, causes endocrinopathy etc.
3, pathology reason.Pituitary pathology, women's reproduction in climacteric hypofunction, hypothyroidism, adrenal cortex secreting function are hyperfunction, nervous centralis disease such as postencephalitis etc. all can make health generation morbid oberity.
4, old and feeble performance.After people in middle age, metabolism is slowed down, and produces inertia on the physiology, and motion reduces, and drug on the market in nutrition, causes fat, and especially behind the female fertility, abdominal muscles is lax, and endocrinopathy is recovered the bodily form as not noting in time taking exercise, and is easy to cause fat.
Studies show that, treat the biologic product of above-mentioned symptom at present and on result of treatment, can not satisfy the demand, palliate the agonizing sufferings for the patient better; The reasonable prescription of minority drug effect is also arranged and become agent, but the mode of the taking drug effect absorption difference of patent medicine does not reach the purpose of effective treatment; The safety of medicine performance is poor, and side effect is big, easily bounce-back; As hospitalization expense height, do not accepted by the patient.
Summary of the invention
The purpose of this invention is to provide that a kind of pharmacy cost is low, instant, treatment and health-care effect obviously, multi-function health care food that human body is had no side effect.
A kind of food that is used for the treatment of fat all cards and prevents its related complication, the technical scheme that is provided is: get flour 90-95kg, starch 10-15kg, granulated sugar (using) 25-30kg with syrup form, edible oil 10-15kg, salt 7-10kg, egg 4-6kg, red sage root 3-4kg, hawthorn 5-6kg, tuber of multiflower knotweed 3-5kg, pseudo-ginseng 7-9kg, chrysanthemum 5-7kg, Ligusticum wallichii 3-7kg, fruit of Chinese wolfberry 6-8kg, purslane 4-7kg, earlier Chinese medicine is cleaned, decoct twice, after concentrating after filtration, add yolk, liquid syrup and face, mould compacting then, the biscuit of finished product gained under 200～280 ℃ of hot conditions.
For realizing that preparation method provided by the present invention may further comprise the steps:
A, accent powder: Chinese medicine is cleaned up, decoct twice, concentrate after filtration, add water 18-20%, syrup, egg yolk liquid and face, use two vertical accent powder machines of starching, transferred approximately 20-25 minute;
B, leave standstill: left standstill 10-15 minute;
C, pressure surface: about 10-11 time;
D, moulding: cut or develop and print with roller;
E, baking: low temperature toasts for a long time, if temperature can be toasted 4-6 minute at 225-250 degree centigrade;
F, cooling: cooling near room temperature, is packed when being lower than 45 degrees centigrade fully;
The Chinese medicine Ligusticum wallichii is the dry rhizome of samphire Ligusticum wallichii, and property suffering, temperature have blood-activating and qi-promoting, wind-expelling pain-stopping, open effects such as strongly fragrant eliminating dampness.
(1) traditional Chinese medical theory is thought Ligusticum wallichii " Xin Xiang walks to scurry and promoting the circulation of qi; promoting blood circulation is with hemostasis; the up head and dispeling the wind; be lowered to the sea of blood with menstruation regulating; and outer thorough fur, and the bypass four limbs are the gas medicine in the blood ", so be usually used in taking orally, cure mainly that headache is dizzy, illnesss such as arthralgia due to wind-dampness, sternal rib shouting pain, treating swelling and pain by traumatic injury, amenorrhoea dysmenorrhoea, irregular menstruation, arthritis spasm, ulcer sores and stasis of blood resistance in postpartum stomachache.
(2) Ligusticum wallichii both had been gynaecology's key medicine, was again treatment headache good recipe, was celebrated with the headache for the treatment of reason chill, wind-heat, the deficiency of blood especially.The modern medicine scientific research is found, the Ligusticum wallichii extract has certain effect to suppressing the leukaemia, pharmaceutical research confirms that the Ligusticum wallichii preparation has certain antibacterial action, especially typhoid bacillus, paratyphosum Bacterium, comma bacillus, Pseudomonas aeruginosa and pathogenic dermatophyte etc. is all had inhibitory action.
(3) ligustrazine, the forulic acid that is contained in the Ligusticum wallichii received and had blood circulation invigorating efficacies, and expansible coronary artery is promoted coronary flow, allevating angina pectoris, and have anti-thrombosis function; Contained ligustilide has smooth muscle spasmolysis and suppresses effects such as myenteron, uterine contractile; The Ligusticum wallichii preparation also has anti-radioactive ray effect.
(4) Ligusticum wallichii also is the main component of multiple Chinese patent drug, all contains Ligusticum wallichii such as Chinese patent drugs such as beneficial female ball commonly used, genseng Qufengbaidu pill, general tonic pill, Zaizao san, Baizi Yangxin Pills, Yueju Wan.
(5) but Ligusticum wallichii is a gas medicine in the blood, Xin Wen walks to scurry and promoting the circulation of qi, in use should note dialectical and taboo, all fire excess from yin deficiency, down empty go up contain, the liver-yang fire is contained, old gas is weak, circulation of vital energy in the wrong direction vomiting, menorrhalgia etc. all should be avoided usefulness.
The red sage root contains various active compositions such as danshensu, danshensu, tanshinone, have promoting blood circulation and removing blood stasis, the effect of regulating qi-flowing for relieving pain, be used for the treatment of coronary heart disease, angina pectoris etc., in recent years be widely used in the multiple hepatopathy of treatment again, comprise acute, chronic hepatitis, fatty liver, liver fibrosis, liver ascites etc., along with going deep into of pharmacological research, Treated with Radix Salviae Miltiorrhizae demonstrates more and more wide prospect aspect hepatopathy, it has mainly acted on the following aspects:
(1) to the protective effect of hepatic injury.Experimental studies have found that, hypodermic injection red sage root water decoction-alcohol sedimentation liquid can make hepatic injury rabbit ALT obviously descend, inflammatory reaction such as cell cloudy swelling, steatosis and necrosis all alleviate than control group, and the red sage root pours into the irreversible hepatic injury that causes after effectively postponing and alleviate ischemic again.Detect hepatic tissue by setting up rat alcoholic liver cellular damage model, show that the red sage root can alleviate hepatic cell fattydegeneration due to the alcohol and downright bad and suppress TG content.For rabbit hepatic ischemia model, the red sage root can obviously alleviate mitochondria and the swelling of coarse grain endoplasmic reticulum.To the cold ischemia-reperfusion injury model of pig, the red sage root can alleviate the liver cell cloudy swelling, fat becomes and the portal area inflammation.
(2) to the facilitation of liver cell regeneration.Behind rat execution partially hepatectomized, give danshen injections, discovery is synthesized DNA in the liver cell obvious facilitation, can quicken cell division propagation and regeneration, use SPECT simultaneously and survey the effective CBF variation of the residual liver of mouse, find that red sage root notes body liquid can obviously improve the effective CBF of residual liver, makes it recover normal in 7 days in postoperative.
(3) effect of anti hepatic fibrosis.The red sage root can make the fibroblast of in vitro culture that significant morphological change takes place, and can suppress the nuclear fission and the propagation of cell, and the liver fibrosis of immunological liver cellular damage is had protective effect.The rat liver fibrosis model that adopts carbon tetrachloride and N-nitrosodimethylamine to induce, compare with colchicin, observe liver histopathology, detect hepatic tissue HgP, MDA (MDA), SOD and serum liver function, the red sage root all shows good anti-fibrosis effect in two kinds of models as a result, and can significantly improve the SOD activity, reduce MDA content, collagenic supersession is also had direct effect.
(4) remove the effect of liver cell oxygen radical.Set up rat liver and preserve re-perfusion model, detect Liver Allograft Preservation respectively after 0 hour, 8 hours, 16 hours, 24 hours, 32 hours, observe the variation of SOD, MDA and perfusion liquid AST at different infusion time points, and the morphologic change of observation liver cell, result and normal group (preserving 0 hour group) are relatively, preserve that 16 hours, 24 hours, 32 hours group differences pour into that a SOD significantly reduces again and MDA and AST all obviously raise, abnormal change also takes place in the liver cell form.Use red sage root group, SOD obviously raises, and MDA and AST obviously descend, and with control group notable difference are arranged more all.
(5) prevent and treat the hepatoma Metastasis recurrence.Experimental results show that, the SMMC-7721 HCC adhesion molecule expression that the red sage root is handled is starkly lower than control group, the red sage root can be controlled the invasive ability of 7721 cells, the cell detachment that promotion has adhered to, also can control the adhesion of lymphocyte, endothelial cell, and in the liver after the early stage and late period liver cancer resection in nude mice and DISTANT METASTASES IN recur preventive and therapeutic effect arranged.
(6) improve the cirrhosis portal hypertension.By the quiet high pressure patient's of cirrhosis door Hemodynamics is discovered, that the red sage root can improve is weak, it is poor to receive, abdominal distension and liver function, effectively reduces bilirubin.
(7) improve the donor Liver Allograft Preservation.Adopt the stripped acyclic perfusion model of rat liver, preserved rat liver 12 hours after in Lactated Ringer'S Solution, adding the various dose red sage root, red sage root group (600mg/g) hepatic tissue ATP content and secretion of bile amount are apparently higher than control group, 2,3-protocatechuic acid, 2.5-protocatechuic acid and outflow liquid aspartic transaminase are starkly lower than control group (P＜0.05).
Pseudo-ginseng is the piece root of araliaceae ginseng plant pseudo-ginseng, and sweet, little hardship of distinguishing the flavor of has removing blood stasis and hemostasis, the effect of the analgesic therapy of invigorating blood circulation.
(1) to the effect of blood and hemopoietic system
1, pseudo-ginseng has good hemostasia effect, can obviously shorten hemorrhage and the clotting time.
Studies show that the hemostatic compositions of pseudo-ginseng is mainly dencichine (Dencichine), dencichine can impel platelet aggregation, distortion, discharges material such as ADP, antihemophilic factor II and calcium ion and reaches anastalsis.
2, pseudo-ginseng can promote all kinds of haemocyte merisis, increase number, promotes proliferation of bone marrow cells and dispose procedure, increases erythrocytic quantity of marrow and activity, reaches the function that promotes hematopoiesis.Experiment finds that pseudo-ginseng can obviously be improved the erythrocyte quantity of blood loss anemia pathological model (rat and rabbit), and blood loss anemia is had therapeutic action preferably; Arasaponin the total white blood cells, can also significantly improve the macrophage phagocytic rate in improving the white mouse peripheral blood, improve the percentage of blood medium size lymphocyte.
3, pseudo-ginseng has obvious curative effects promoting blood circulation and removing blood stasis, eliminate blood stasis and promote tissue regeneration.
The notoginseng total saponin that extracts from pseudo-ginseng has antagonism to arrhythmia cordis, can improve the ventricle electricity simultaneously and cause the threshold that quivers, and it has two kinds of mechanism of action, and the one, the homogeneity of the myocardium refractory period of raising, elimination is turned back; Two may be that prolongation reciprocal excitation wave-wave is grown and termination is turned back, and can also suppress the conduction of sinoatrial node self-disciplining and antrum.
(2) to the effect of cardiovascular system
The traditional Chinese medical science with pseudo-ginseng as activating blood and removing stasis drug treat coronary heart disease, angina pectoris obtains significant curative effect.Blood viscosity is too high to be the main root of diseases in the blood system such as coronary heart disease, angina pectoris, cerebral hemorrhage, and pseudo-ginseng has the activity that suppresses platelet aggregation, promotes fibrinolysin, reduces blood viscosity, promotes thrombolysis, improves the effect of blood flow.
Experiment shows that the notoginseng triterpenes effect of invigorating blood circulation can be expanded cardiovascular, increases coronary flow, suppresses thrombosis, platelet aggregation-against, and can dissolve established thrombus, having additional nutrients property MBF; Simultaneously, pseudo-ginseng also can reduce angiosthenia, slightly subtracts heart rate, and the heart working amount is lowered, thereby obviously reduces the oxygen demand of cardiac muscle, can be used for treating myocardial ischemia, angina pectoris and shock.
(3) to neural effect
Studies show that, both contained protopanoxadiol type saponin(e in the pseudo-ginseng, also contain Protopanaxatriol's type saponin(e, wherein, protopanoxadiol type saponin(e has the nervous centralis inhibitory action, and Protopanaxatriol's type saponin(e has the central nervous excitation effect.Clinical practice proves that pseudo-ginseng part (sanchi flower, leaf, stem) on the ground has inhibitory action to nervous centralis, shows as calmness, stabilizes and improve functions such as sleep, and total saponin(e analgesia of sanchi leaf and sedation are very obvious; Pseudo-ginseng under ground portion (pseudo-ginseng root) energy stimulating central nervous system improves mentality and physical, shows fatigue resistance.
(4) anti-inflammatory effect
Pharmacological evaluation shows, the capillary permeability that pseudo-ginseng causes acute inflammation increases, inflammatory oozes out, tissue edema, leukoplania and later stage granulation tissue hyperplasia all have the obvious suppression effect, antiinflammatory action mechanism is the scorching effect of existing direct a heatable brick bed, also has by bringing into play antiinflammatory action between excited hypophysis-interrenal system.
(5) to immune effect
Notoginseng polysaccharide is the active ingredient that promotes immunity, two kinds of polysaccharide of pseudo-ginseng all can be urged the function through macrophage, notoginseng triterpenes also can improve blood middle leukocytes sum and lymphocyte percentage, promotes the hyperplasia of candidate stem cell, the generation that can also improve humoral immunity antibody to a certain extent.
Chrysanthemum is the dry capitulum of feverfew chrysanthemum, is conventional Chinese medicine, the effect of have dispelling wind, heat-clearing, make eye bright, detoxifying, diseases such as main treatment headache, dizzy, hot eyes, ambition dysphoria with smothery sensation, furunculosis, pyogenic infections.Modern pharmacological research shows, chrysanthemum has treatment coronary heart disease, brings high blood pressure down, prevents high fat of blood, antibiotic, antiviral, anti-inflammatory, the anti-ageing multiple pharmacologically active of waiting for a long time:
1, cardiovascular aspect pharmacological action.The phenol position of chrysanthemum can increase the heart coronary flow, improves the tolerance of body to the decompression anoxic, and the total extract of chrysanthemum all shows to have positive inotropic action to isolated heart, cardiac muscle cell.
2, antivirus action.Discover that chrysanthemum is to herpes simplex virus, poliovirus and measles virus have inhibitory action in various degree.In addition, chrysanthemum also has the effect of anti-AIDS, can suppress the activity that Zv reverse transcriptase and HLV duplicate, wherein from chrysanthemum separate obtain acacetin-7-O-β-the D-galactolipin is its active component, and toxicity is very little.
3, anti-aging effects.Chrysanthemum can strengthen the glutathione peroxidating and reduce; obviously prolong the silkworm life-span; can also improve the heart and brain resisting oxygen lack; the ability that prolongs life span and remove free radical; biomembranous ultra-oxygen anion free radical damage is had obvious protective effect, mainly is by shielding behind the glyceride that directly enters cell membrane.
4, antitumor action.Separating the taraxerane type triterpene alcohols obtain from chrysanthemum has than significant inhibitory effect skin neoplasin, in addition 60 kinds of human tumor cells such as kinds of tumor such as lung cancer, colon cancer, kidney, oophoroma, the cancer of the brain, leukaemia is had extremely significant cytotoxic activity.
Purslane is the herb of dicotyledon medicine portulacaceous plant purslane, and clearing heat and promoting diuresis is arranged, removing pattogenic heat from the blood and toxic material from the body, and the effect of only quenching one's thirst, pharmacological action has:
1, short ulcer healing effect: this product contains abundant vitamin A sample material, so can promote epithelial physiological function to be tending towards normal.
2, antibacterial and antifungic action: Escherichia coli, shigella dysenteriae, typhoid bacillus are all had remarkable inhibitory action; Common pathogenic dermatophyte there is in various degree inhibitory action.
3, to the effect of uterus and vascular smooth muscle: blood vessel is also had contraction, and this kind contraction has maincenter and tip concurrently.
4, step-down, diuresis and reinforcement enterocinesia effect are arranged.
Food of the present invention compared with prior art, it need not be taken medicine, have an injection, also without hospitalization, instant, cost of manufacture is low, and the medicinal treatment more commonly used than doctor trained in Western medicine makes the patient satisfaction rate improve 30%, cure rate reaches 20%, efficient more than 90%, find no any toxic and side effect, especially remarkable to treating fat all card effects.In addition, the present invention also can be used as health care leisure food commonly used, has the effect of promoting digestion and removing indigestion, clearing damp and promoting diuresis, lowering blood-fat and reducing weight, and it is edible to be fit to the four seasons, has no side effect, and better economic and social benefit are arranged.
Specific embodiments
In the actual pharmacy, can be with flour 90-95kg, starch 10-15kg, granulated sugar (using) 25-30kg with syrup form, edible oil 10-15kg, salt 7-10kg, egg 4-6kg, red sage root 3-4kg, hawthorn 5-6kg, tuber of multiflower knotweed 3-5kg, pseudo-ginseng 7-9kg, chrysanthemum 5-7kg, Ligusticum wallichii 3-7kg, fruit of Chinese wolfberry 6-8kg, purslane 4-7kg, earlier Chinese medicine is cleaned, decoct twice, after concentrating after filtration, add yolk, liquid syrup and face, mould compacting then, the biscuit of finished product gained under 200～280 ℃ of hot conditions.
Below in conjunction with embodiment content of the present invention is described further:
Embodiment one
Compatibility is: flour 90-95kg, starch 10-15kg, granulated sugar (using with syrup form) 25-30kg, edible oil 10-15kg, salt 7-10kg, egg 4-6kg, red sage root 3-4kg, hawthorn 5-6kg, tuber of multiflower knotweed 3-5kg, pseudo-ginseng 7-9kg, chrysanthemum 5-7kg, Ligusticum wallichii 3-7kg, fruit of Chinese wolfberry 6-8kg, purslane 4-7kg.
The preparation method:
A, accent powder: Chinese medicine is cleaned up, decoct twice, concentrate after filtration, add water 18-20%, syrup, egg yolk liquid and face, use two vertical accent powder machines of starching, transferred approximately 20-25 minute;
B, leave standstill: left standstill 10-15 minute;
C, pressure surface: about 10-11 time;
D, moulding: cut or develop and print with roller;
E, baking: low temperature toasts for a long time, if temperature can be toasted 4-6 minute at 225-250 degree centigrade;
F, cooling: cooling near room temperature, is packed when being lower than 45 degrees centigrade fully;
Embodiment two
Compatibility is: flour 95kg, starch 15kg, granulated sugar (using with syrup form) 30kg, edible oil 15kg, salt 10kg, egg 6kg, red sage root 4kg, hawthorn 6kg, tuber of multiflower knotweed 5kg, pseudo-ginseng 9kg, chrysanthemum 7kg, Ligusticum wallichii 7kg, fruit of Chinese wolfberry 8kg, purslane 7kg, its preparation method is with embodiment one.
Embodiment three
Compatibility is: flour 90kg, starch 10kg, granulated sugar (using with syrup form) 25kg, edible oil 10kg, salt 7kg, egg 4kg, red sage root 3kg, hawthorn 5kg, tuber of multiflower knotweed 3kg, pseudo-ginseng 7kg, chrysanthemum 5kg, Ligusticum wallichii 3kg, fruit of Chinese wolfberry 6kg, purslane 4kg, its preparation method is with embodiment one.
In sum, biscuity of the present invention is sweet, little sweet, its amount can be divided into treatment and keep healthy two kinds, edible when have hunger every day for the patient, each consumption is decided according to the personal considerations, do not limit as ordinary person's health food edible time, the present invention is without any side effects, drug safety performance height, but every day is edible, and each medicine in the compatibility and preparation method thereof is to select for use according to " Pharmacopoeia of People's Republic of China ".
The rationale of the present invention treatment is that the red sage root, hawthorn, the tuber of multiflower knotweed, pseudo-ginseng, chrysanthemum, Ligusticum wallichii, the fruit of Chinese wolfberry, purslane with promoting digestion and removing indigestion, clearing damp and promoting diuresis, lowering blood-fat and reducing weight etc. is raw material, by directly edible mode administration, the drug effect good absorbing, show through clinical testing, the present invention has good antiobesity action, efficient more than 90%, for the fat all cards of clinical treatment provide strong foundation.
Claims (3)
1, a kind of multi-flavor fat-decreasing biscuit is characterized in that being made up of following formulation ratio: get flour 90-95kg, starch 10-15kg, granulated sugar (using) 25-30kg with syrup form, edible oil 10-15kg, salt 7-10kg, egg 4-6kg, red sage root 3-4kg, hawthorn 5-6kg, tuber of multiflower knotweed 3-5kg, pseudo-ginseng 7-9kg, chrysanthemum 5-7kg, Ligusticum wallichii 3-7kg, fruit of Chinese wolfberry 6-8kg, purslane 4-7kg, earlier Chinese medicine is cleaned, decoct twice, after concentrating after filtration, add yolk, liquid syrup and face, mould compacting then, the biscuit of finished product gained under 200～280 ℃ of hot conditions.
2, according to claim 1, it is characterized in that the preparation method is:
A, accent powder: Chinese medicine is cleaned up, decoct twice, concentrate after filtration, add water 18-20%, syrup, egg yolk liquid and face, use two vertical accent powder machines of starching, transferred approximately 20-25 minute;
B, leave standstill: left standstill 10-15 minute;
C, pressure surface: about 10-11 time;
D, moulding: cut or develop and print with roller;
E, baking: low temperature toasts for a long time, if temperature can be toasted 4-6 minute at 225-250 degree centigrade;
F, cooling: cooling near room temperature, is packed when being lower than 45 degrees centigrade fully.
3, according to claim 1, it is characterized in that forming: flour 95kg, starch 15kg by following formulation ratio, granulated sugar (using) 30kg with syrup form, edible oil 15kg, salt 10kg, egg 6kg, red sage root 4kg, hawthorn 6kg, tuber of multiflower knotweed 5kg, pseudo-ginseng 9kg, chrysanthemum 7kg, Ligusticum wallichii 7kg, fruit of Chinese wolfberry 8kg, purslane 7kg, the preparation method is the same.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100244237A CN101073332A (en) | 2007-06-15 | 2007-06-15 | Lipid-lowering biscuit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100244237A CN101073332A (en) | 2007-06-15 | 2007-06-15 | Lipid-lowering biscuit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101073332A true CN101073332A (en) | 2007-11-21 |
Family
ID=38974736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007100244237A Pending CN101073332A (en) | 2007-06-15 | 2007-06-15 | Lipid-lowering biscuit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101073332A (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102379324A (en) * | 2011-10-18 | 2012-03-21 | 亳州药王谷生物科技有限公司 | Heart-nourishing biscuit and preparation method thereof |
| CN103222492A (en) * | 2013-03-29 | 2013-07-31 | 薛朝贵 | Chicken bone purslane codonopsis pilosula biscuit and making method thereof |
| CN103315025A (en) * | 2013-03-29 | 2013-09-25 | 薛朝贵 | Aralia elata seem kidney-tonifying biscuits and preparation method thereof |
| CN103315219A (en) * | 2013-03-30 | 2013-09-25 | 安徽金禾粮油集团有限公司 | Bean-dreg fruit steamed bread and preparation method thereof |
| CN103380797A (en) * | 2013-06-25 | 2013-11-06 | 吴瑞凤 | Peanut spring roll and processing method thereof |
| CN103404568A (en) * | 2013-08-07 | 2013-11-27 | 马文化 | Rhizoma chuanxiong shrimp shell biscuits and preparation method thereof |
| CN103430996A (en) * | 2013-07-25 | 2013-12-11 | 柳培健 | Method for making biscuit from distilled grain |
| CN103503943A (en) * | 2012-06-18 | 2014-01-15 | 贵州神奇集团控股有限公司 | Lipid-lowering biscuit and preparation method thereof |
| CN103535408A (en) * | 2013-10-08 | 2014-01-29 | 曹石 | Method for making polygonum multiflorum powder nutritious biscuits |
| CN103583647A (en) * | 2013-10-17 | 2014-02-19 | 安徽金禾粮油集团有限公司 | Biscuit with fermented bean curd and fishskin and biscuit preparation method |
| CN103598292A (en) * | 2013-10-15 | 2014-02-26 | 鲁杨 | Chrysanthemum herba leucatis molloissimae biscuit |
| CN103931708A (en) * | 2014-03-18 | 2014-07-23 | 桂玉平 | Health care biscuit for preventing and treating hyperlipidemia and production method of health care biscuit |
| CN104904805A (en) * | 2015-05-28 | 2015-09-16 | 南京大地冷冻食品有限公司 | Slimming biscuit |
| CN107637631A (en) * | 2017-11-27 | 2018-01-30 | 常德炎帝生物科技有限公司 | A kind of nostoc biscuit with health-care efficacy and preparation method thereof |
| CN109717230A (en) * | 2019-03-20 | 2019-05-07 | 广南亿安食品有限公司 | A kind of biscuit and preparation process based on Notogineng Extract preparation |
-
2007
- 2007-06-15 CN CNA2007100244237A patent/CN101073332A/en active Pending
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102379324B (en) * | 2011-10-18 | 2013-02-27 | 亳州药王谷生物科技有限公司 | Heart-nourishing biscuit and preparation method thereof |
| CN102379324A (en) * | 2011-10-18 | 2012-03-21 | 亳州药王谷生物科技有限公司 | Heart-nourishing biscuit and preparation method thereof |
| CN103503943A (en) * | 2012-06-18 | 2014-01-15 | 贵州神奇集团控股有限公司 | Lipid-lowering biscuit and preparation method thereof |
| CN103503943B (en) * | 2012-06-18 | 2015-07-01 | 贵州神奇集团控股有限公司 | Lipid-lowering biscuit and preparation method thereof |
| CN103222492A (en) * | 2013-03-29 | 2013-07-31 | 薛朝贵 | Chicken bone purslane codonopsis pilosula biscuit and making method thereof |
| CN103315025A (en) * | 2013-03-29 | 2013-09-25 | 薛朝贵 | Aralia elata seem kidney-tonifying biscuits and preparation method thereof |
| CN103315025B (en) * | 2013-03-29 | 2015-04-08 | 薛朝贵 | Aralia elata seem kidney-tonifying biscuits and preparation method thereof |
| CN103315219A (en) * | 2013-03-30 | 2013-09-25 | 安徽金禾粮油集团有限公司 | Bean-dreg fruit steamed bread and preparation method thereof |
| CN103315219B (en) * | 2013-03-30 | 2015-11-25 | 安徽金禾粮油集团有限公司 | A kind of bean dregs fruit steamed bun and preparation method thereof |
| CN103380797A (en) * | 2013-06-25 | 2013-11-06 | 吴瑞凤 | Peanut spring roll and processing method thereof |
| CN103380797B (en) * | 2013-06-25 | 2015-11-25 | 吴瑞凤 | One cultivates peanut spring roll and processing method thereof |
| CN103430996A (en) * | 2013-07-25 | 2013-12-11 | 柳培健 | Method for making biscuit from distilled grain |
| CN103404568A (en) * | 2013-08-07 | 2013-11-27 | 马文化 | Rhizoma chuanxiong shrimp shell biscuits and preparation method thereof |
| CN103535408A (en) * | 2013-10-08 | 2014-01-29 | 曹石 | Method for making polygonum multiflorum powder nutritious biscuits |
| CN103598292A (en) * | 2013-10-15 | 2014-02-26 | 鲁杨 | Chrysanthemum herba leucatis molloissimae biscuit |
| CN103598292B (en) * | 2013-10-15 | 2016-01-27 | 鲁杨 | A kind of chrysanthemum north wind grass biscuit |
| CN103583647A (en) * | 2013-10-17 | 2014-02-19 | 安徽金禾粮油集团有限公司 | Biscuit with fermented bean curd and fishskin and biscuit preparation method |
| CN103931708B (en) * | 2014-03-18 | 2015-12-30 | 桂玉平 | A kind of health-caring biscuit and production method thereof of preventing and treating high fat of blood |
| CN103931708A (en) * | 2014-03-18 | 2014-07-23 | 桂玉平 | Health care biscuit for preventing and treating hyperlipidemia and production method of health care biscuit |
| CN104904805A (en) * | 2015-05-28 | 2015-09-16 | 南京大地冷冻食品有限公司 | Slimming biscuit |
| CN107637631A (en) * | 2017-11-27 | 2018-01-30 | 常德炎帝生物科技有限公司 | A kind of nostoc biscuit with health-care efficacy and preparation method thereof |
| CN109717230A (en) * | 2019-03-20 | 2019-05-07 | 广南亿安食品有限公司 | A kind of biscuit and preparation process based on Notogineng Extract preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101073332A (en) | Lipid-lowering biscuit | |
| CN108524776B (en) | Medicine for treating qi-yin deficiency type diabetes and preparation method thereof | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN101946895B (en) | Functional food taking loach as main material and preparation method thereof | |
| CN101085039A (en) | Composition for preventing and treating diabetes (hyperglycaemia) and its preparation method | |
| CN103099842A (en) | Soft capsule helpful for increasing bone density and preparation method thereof | |
| CN103223087A (en) | Food therapy formula for treating diabetes mellitus | |
| CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN103385931B (en) | Blood-sugar-lowering medicine composition | |
| CN102049010B (en) | Medicament for preventing and treating ischemic cerebrovascular diseases | |
| CN101164558B (en) | Clot-dispersing pain-relieving medicinal composition and preparation method and application thereof | |
| CN103525640B (en) | Energy-keeping yang-tonifying wine | |
| CN103977112B (en) | A kind of Chinese medicine treating alcoholic liver | |
| CN104825922A (en) | Traditional Chinese medicine composition with anti-colorectal cancer activity and preparation method and application of traditional Chinese medicine composition | |
| CN103948666B (en) | Preparation method of Tibetan medicine for treating diabetes | |
| CN110841008A (en) | Black-bone sheep placenta confinement wine and preparation method thereof | |
| CN108186905A (en) | A kind of Chinese medicine composition for treating extreme heat due to deficiency of yin patients with type Ⅰ DM and preparation method thereof | |
| CN1256976C (en) | Anti-cancer Chinese medicinal composition and its preparing method | |
| CN104666328A (en) | Application of traditional Chinese medicine polysaccharide in medicine and extraction method of traditional Chinese medicine polysaccharide | |
| CN105125886A (en) | Traditional Chinese medicine composition for preventing and treating diabetes and complications of diabetes | |
| CN103961392B (en) | Traditional Tibetan medicine for treating diabetes | |
| CN104524334A (en) | Traditional Chinese medicine composition for elder pneumonia in adjuvant therapy | |
| CN105726849B (en) | It is a kind of for treating the Chinese medicine of diabetes Depression | |
| CN104840727B (en) | Chinese medicine composition with anti-cancer of the esophagus activity and its preparation method and application | |
| CN102600244A (en) | Chinese medicinal granules for treating liver cancer and protecting liver functions, as well as preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20071121 |